Posted by Michael Wonder on 20 Jul 2021
US FDA approves fexinidazole as the first all oral treatment for sleeping sickness
19 July 2021 - US FDA approves fexinidazole as the first all-oral treatment for sleeping sickness.
The US FDA has approved fexinidazole as the first all-oral treatment for both stages of the Trypanosoma brucei gambiense form of sleeping sickness (human African trypanosomiasis) in patients 6 years of age and older and weighing at least 20 kg.
Fexinidazole was developed as part of an innovative partnership between the non-profit research and development organisation Drugs for Neglected Diseases initiative, which conducted the pivotal clinical trials for this treatment, in partnership with the National Sleeping Sickness Programs of the Democratic Republic of Congo and Central African Republic, and Sanofi.
